Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Strezova, Ana, Diez-Domingo, Javier, Al Shawafi, Kamal, Tinoco, Juan Carlos, Shi, Meng, Pirrotta, Paola, Mwakingwe-Omari, Agnes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588150/
https://www.ncbi.nlm.nih.gov/pubmed/36299530
http://dx.doi.org/10.1093/ofid/ofac485
_version_ 1784814064944283648
author Strezova, Ana
Diez-Domingo, Javier
Al Shawafi, Kamal
Tinoco, Juan Carlos
Shi, Meng
Pirrotta, Paola
Mwakingwe-Omari, Agnes
author_facet Strezova, Ana
Diez-Domingo, Javier
Al Shawafi, Kamal
Tinoco, Juan Carlos
Shi, Meng
Pirrotta, Paola
Mwakingwe-Omari, Agnes
author_sort Strezova, Ana
collection PubMed
description Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years.
format Online
Article
Text
id pubmed-9588150
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95881502022-10-25 Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination Strezova, Ana Diez-Domingo, Javier Al Shawafi, Kamal Tinoco, Juan Carlos Shi, Meng Pirrotta, Paola Mwakingwe-Omari, Agnes Open Forum Infect Dis Brief Report Approximately 10 years after vaccination with the recombinant zoster vaccine (RZV), an interim analysis of this follow-up study of the ZOE-50/70 trials demonstrated that efficacy against herpes zoster remained high. Moreover, the safety profile remained clinically acceptable, suggesting that the clinical benefit of the RZV in ≥50-year-olds is sustained up to 10 years. Oxford University Press 2022-10-23 /pmc/articles/PMC9588150/ /pubmed/36299530 http://dx.doi.org/10.1093/ofid/ofac485 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Strezova, Ana
Diez-Domingo, Javier
Al Shawafi, Kamal
Tinoco, Juan Carlos
Shi, Meng
Pirrotta, Paola
Mwakingwe-Omari, Agnes
Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title_full Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title_fullStr Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title_full_unstemmed Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title_short Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination
title_sort long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity, and safety results up to 10 years after initial vaccination
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9588150/
https://www.ncbi.nlm.nih.gov/pubmed/36299530
http://dx.doi.org/10.1093/ofid/ofac485
work_keys_str_mv AT strezovaana longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT diezdomingojavier longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT alshawafikamal longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT tinocojuancarlos longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT shimeng longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT pirrottapaola longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT mwakingweomariagnes longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination
AT longtermprotectionagainstherpeszosterbytheadjuvantedrecombinantzostervaccineinterimefficacyimmunogenicityandsafetyresultsupto10yearsafterinitialvaccination

Ejemplares similares